Business Wire10.18.18
Saranas Inc., a medical device company with technology for real-time detection and monitoring of internal bleeding during endovascular procedures, announced that the first clinical cases with Early Bird Bleed Monitoring System were performed at Atlantic Health System’s Morristown Medical Center (Morristown, N.J.). The cases varied across multiple interventions including transcatheter aortic valve replacement (TAVR), hemodynamic support and standard percutaneous coronary interventions, demonstrating the versatility of the Early Bird to potentially improve patient safety with improved bleed status monitoring during and after endovascular access procedures.
"The Early Bird Bleed Monitoring System is designed to protect, and in some cases, save the lives of patients undergoing an endovascular procedure by allowing physicians to detect the onset of bleeding early and take appropriate steps to address the bleed before detrimental, irreversible, and life-threatening consequences occur,” said Saranas Chief Medical Officer Dr. Philippe Généreux. “The initial clinical cases have successfully demonstrated the versatility and potential benefit of the Early Bird across a wide variety of case types.”
The Early Bird Bleed Monitoring System includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as TAVR, large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.
The Early Bird Bleed Monitoring System is not yet approved by the U.S. Food and Drug Administration and is currently available for investigational use only.
"Our goal in the development of the Early Bird Bleed Monitoring System is to provide doctors with a groundbreaking tool to reduce bleeding complications and to improve clinical outcomes in patients undergoing endovascular procedures," said Zaffer Syed, president and CEO of Saranas. “As we expand our clinical pilot to multiple U.S. centers in the coming weeks, we look forward to gaining more insight and experience on the utility of bleed monitoring.”
Saranas is a privately held Houston, Texas-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs.
"The Early Bird Bleed Monitoring System is designed to protect, and in some cases, save the lives of patients undergoing an endovascular procedure by allowing physicians to detect the onset of bleeding early and take appropriate steps to address the bleed before detrimental, irreversible, and life-threatening consequences occur,” said Saranas Chief Medical Officer Dr. Philippe Généreux. “The initial clinical cases have successfully demonstrated the versatility and potential benefit of the Early Bird across a wide variety of case types.”
The Early Bird Bleed Monitoring System includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as TAVR, large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.
The Early Bird Bleed Monitoring System is not yet approved by the U.S. Food and Drug Administration and is currently available for investigational use only.
"Our goal in the development of the Early Bird Bleed Monitoring System is to provide doctors with a groundbreaking tool to reduce bleeding complications and to improve clinical outcomes in patients undergoing endovascular procedures," said Zaffer Syed, president and CEO of Saranas. “As we expand our clinical pilot to multiple U.S. centers in the coming weeks, we look forward to gaining more insight and experience on the utility of bleed monitoring.”
Saranas is a privately held Houston, Texas-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs.